 |
 |
 |
 |
 |
 |
  |
Board of Directors Andrew Sandham, (Chairman) |
LeadershipManagement Team |
Deepa Pakianathan, PhD, General Partner, Delphi Ventures Deepa joined Delphi Ventures in 2001 and leads the firms’ biotechnology investment activities. Prior to joining Delphi, Deepa was a Vice President in the healthcare group at JP Morgan where she was involved in healthcare M&A transactions worth in excess of $6 billion and public offerings for biotechnology companies that raised more than $9 billion in capital. From 1997 to 1998, Deepa was a biotechnology research analyst at Genesis Merchant Group. She worked as a postdoctoral scientist in the Immunology Department at Genentech Corporation from 1993 to 1997, where she evaluated chemokines and chemokine receptors as targets for therapeutic intervention. |
|